SNSE Sensei Biotherapeutics, Inc.

NEUTRAL Impact: 5/10 DEFA14A
Horizon days Filed May 21, 2026 Processed 28d 10h ago SEC 0001193125-26-234885
Proxy solicitation materials
Latest settled — T+5d ⚠ clustered
SNSE ▲ +11.24% at T+5d
NEUTRAL call ✓ call won +11.24% · α vs SPY +9.57% · entry $17.79 → $19.79
Next anchor: T+20d in 3d
Currently $17.57 · -1.24% from $17.79 entry
Entry anchored
May 21, 03:59 PM ET
via Databento tick
T+1d
-7.42%
call -7.42% · α -8.01%
$16.47
settled 28d ago
T+5d
+11.24%
call +11.24% · α +9.57%
$19.79
settled 21d ago
T+20d
call — · α —
in 3d
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

Sensei Biotherapeutics filed a DEFA14A proxy supplement providing unaudited pro forma financials for the conversion of Series B Preferred Stock into common stock, scheduled for a shareholder vote on June 10, 2026. The conversion would add ~24.4M shares to the float, massively diluting existing common holders (pro forma share count ~25.7M vs 1.3M actual), but the company holds $152.3M cash and $50.5M in marketable securities post-Faeth acquisition and PIPE. The filing is routine proxy solicitation material with no change to board recommendations.

Actionable Insight

The June 10 vote is a binary catalyst — approval triggers automatic conversion of Series B Preferred into common, massively increasing float and likely pressuring the stock as holders with beneficial ownership limitations may sell. Monitor the vote outcome and any waiver of beneficial ownership limitations by Series B holders, which would determine the actual number of shares converted. The $200M cash runway provides a floor, but the dilution overhang is significant.

Key Facts

  • Annual Meeting scheduled for June 10, 2026; record date April 13, 2026
  • Series B Preferred Stock will automatically convert into ~24.4M shares of common stock three business days after shareholder approval
  • Pro forma weighted-average shares outstanding would increase from 1,295,052 to 25,729,972 (19.9x dilution)
  • Pro forma net loss per share improves from ($131.45) to ($6.62) due to share count increase
  • Company had $152.3M cash and $50.5M marketable securities as of March 31, 2026
  • Series B Preferred Stock was issued in connection with the February 2026 acquisition of Faeth Therapeutics and a concurrent $200M PIPE financing
  • Board of Directors recommendations on all proposals remain unchanged from the Definitive Proxy Statement

Financial Impact

Conversion of Series B Preferred Stock will add ~24.4M common shares, increasing diluted share count ~19.9x from 1.3M to 25.7M. Net loss per share improves from ($131.45) to ($6.62) on a pro forma basis, purely a mechanical effect of denominator expansion. No change to cash position ($152.3M) or total assets ($205.4M).

dilutionshares outstandingnet loss per share

Risk Factors

  • Massive dilution: ~24.4M new shares entering the float could overwhelm current trading liquidity
  • Beneficial ownership limitations may limit conversion, but waivers could increase dilution beyond expectations
  • Stockholder approval may fail, preventing conversion and creating uncertainty around Series B terms
  • Nasdaq listing application approval is a condition to waiver of beneficial ownership limitations

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-234885
Document: 0001193125-26-234885-index-headers.html0001193125-26-234885
Document: 0001193125-26-234885-index.html0001193125-26-234885
Document: 0001193125-26-234885.txt0001193125-26-234885
15 reports for SNSE
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+20▲ +42.80%Apr 28, 2026
Filters
Rows
Reports for SNSE — sortable, filterable
Type Now
Jun 16, 2026
2d ago
3
NEUTRAL ★ 3/10
$13.86 awaiting T+5awaiting T+5$17.57 (+26.77%)
Jun 15, 2026
3d ago
8-K
BEARISH ★ 6/10
$13.04 awaiting T+5awaiting T+5$17.57 (−34.74%)
Jun 15, 2026
4d ago
EFFECT
BEARISH ★ 6/10
$13.04 awaiting T+5awaiting T+5$17.57 (−34.74%)
Jun 10, 2026
8d ago
S-3/A
NEUTRAL ★ 4/10
$10.79 $13.85▲ +28.36%▲ +27.93%$17.57 (+62.84%)
Jun 10, 2026
8d ago
8-K
NEUTRAL ★ 3/10
$10.79 $13.85▲ +28.36%▲ +27.93%$17.57 (+62.84%)
Jun 2, 2026
16d ago
10-K/A
NEUTRAL ★ 3/10
$16.10 $12.63▼ −21.53%▼ −18.56%$17.57 (+9.16%)
Jun 2, 2026
16d ago
S-3/A
BEARISH ★ 6/10
$16.10 $12.63▲ +21.53%▲ +18.56%$17.57 (−9.16%)
Jun 1, 2026
17d ago
Insider Cluster
BEARISH ★ 7/10
$16.10 $12.63▲ +21.53%▲ +18.56%$17.57 (−9.16%)
May 22, 2026
27d ago
DEFA14A
NEUTRAL ★ 3/10
$16.47 $19.79▲ +20.16%▲ +19.07%$17.57 (+6.68%)
May 22, 2026
27d ago
8-K
NEUTRAL ★ 2/10
$16.47 $19.79▲ +20.16%▲ +19.07%$17.57 (+6.68%)
Showing 10 of 15

US Market Status

Market Closed — Juneteenth — Opens Mon (77h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access